Videos

Cheryl Allen, BS Pharm, MBA, founding partner, Curatio Scientia Advisors, highlights how two decades of commercial trade and distribution have transformed the channel from a primarily supply-chain-focused function into a more integrated discipline.

Trade & Channel Strategies 2025: Channel Evolution Over the Last 20 Years

Articles

Subject matter experts from Cencora and FuzeRx explore how modern commercialization models, digital-first pharmacy solutions, and closer provider partnerships are reshaping patient access and adherence across today’s complex therapeutic landscape.

Trade & Channel Strategies 2025: Channel Strategies Evolve, With Industry Leaders Pushing Toward Faster, More Connected Patient Access

Podcasts

In today’s Pharma Pulse, the University of Maryland expands its medical class to combat physician shortages and much more.

Pharma Pulse: FDA Shifts CAR-T Standards and Maryland Expands Medical Class Size, as Pharma Channels Brace for Massive Patent Cliff Disruption

Commercialization expert Bill Roth outlines the critical need for "adaptive capacity," detailing how accelerating government regulation and massive patent cliffs are forcing a complete overhaul of commercial strategies across various markets.

Trade & Channel Strategies 2025: How Regulatory & Patent Cliff Disruption is Remaking Pharma Channels

In the final part of his Pharma Commerce video interview, Colin Banas, MD, DrFirst’s chief medical officer, explains how amid soaring patient and provider frustration, new HTI-4 standards are rapidly forcing change across the insurance and technology sectors to solve the current "transparency problem," making the status of a life-saving prescription as clear and actionable as tracking a takeout order.

HTI-4 Standards Target Lack of Transparency in Medication Access

In today’s Pharma Pulse, new trials confirm AI chatbots are a successful and sustainable tool for increasing pneumococcal vaccine uptake among older adults and much more.

Pharma Pulse: Lilly’s Jaypirca Challenges Imbruvica, as AI Chatbots Could Prove Key to Boosting Vaccine Rates

In the second part of his Pharma Commerce video interview, Colin Banas, MD, DrFirst’s chief medical officer, points out that while real-time benefit tools are improving coverage visibility at the point of care, true efficiency requires actionable insights and standardized ePA, an area still “laying the tracks.”

Price Transparency Advances, Prior Authorization Still Stalls

Artificial intelligence is fundamentally transforming medical affairs from a reactive function into a strategic partner by converting disparate data into "precision medical affairs" insights, driving targeted HCP engagement and operational efficiency. 

How AI-Powered Precision Is Reshaping Medical Affairs 

In today’s Pharma Pulse, the ACIP votes to end the decades-long universal hepatitis B birth dose recommendation; meanwhile, former FDA commissioners warn that new vaccine policies are compromising the long-standing regulatory framework and jeopardizing public health security.

Pharma Pulse: ACIP Ends Universal Hep B Birth Dose 

The entrepreneur urges the Trump administration to eliminate costly FDA generic drug fees, part of a broader push to scale domestic production, address shortages, and challenge PBM-driven pricing models.

News